Age is not a factor in the hospitalization of patients with inflammatory bowel disease treated with vedolizumab and ustekinumab, but comorbidities are, according to a study published in Alimentary Pharmacology & Therapeutics. The risk is higher in patients with comorbidities due to a possible interaction with other medications and poorer response, researchers wrote.
Age not tied to negative outcomes with 2 IBD treatments
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.